

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:

NEW ASSIGNMENT

NATURE OF CONVEYANCE:

ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
MedaSorb Corporation	08/22/2006

RECEIVING PARTY DATA

Name:	Bro-Tech Corporation
Street Address:	150 Monument Road
City:	Bala Cynwyd
State/Country:	PENNSYLVANIA
Postal Code:	19004

PROPERTY NUMBERS Total: 17

Property Type	Number
Application Number:	11255132
Patent Number:	6878127
Patent Number:	6303702
Patent Number:	6159377
Patent Number:	6156851
Patent Number:	6153707
Patent Number:	6136424
Patent Number:	6133393
Patent Number:	6127311
Patent Number:	6114466
Patent Number:	6087300
Patent Number:	5904663
Patent Number:	5773384
Application Number:	11105140
Application Number:	10981055

PATENT

500147570

REEL: 018207 FRAME: 0193

OP \$680.00 11255132

Application Number:	10980510
Application Number:	10038053

CORRESPONDENCE DATA

Fax Number: (212)354-8113

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: (212) 819-8200

Email: jgenova@whitecase.com

Correspondent Name: WHITE & CASE LLP

Address Line 1: 1155 AVENUE OF THE AMERICAS

Address Line 2: PATENT DEPARTMENT

Address Line 4: NEW YORK, NEW YORK 10036

ATTORNEY DOCKET NUMBER:

1136254-0003

NAME OF SUBMITTER:

MARINA ORMAN

Total Attachments: 3

source=1136254-0003#page1.tif

source=1136254-0003#page2.tif

source=1136254-0003#page3.tif

ASSIGNMENT

WHEREAS, MedaSorb Corporation ("MedaSorb"), as successor to White Eagle International Technologies Group, Inc., Advanced Renal Technologies LLC and RenalTech International, LLC, is the assignee and owner of:

- i. U.S. Patent No. 6,878,127 issued on April 12, 2005 and entitled "Devices, Systems, and Methods for Reducing Levels of Pro-Inflammatory or Anti-Inflammatory Stimulators or Mediators in the Blood";
- ii. U.S. Patent No. 6,303,702 issued on October 16, 2001 and entitled "Method of Producing Material for Purification of Physiological Liquids of Organism";
- iii. U.S. Patent No. 6,159,377 issued on December 12, 2000 and entitled "Method of Purification of Physiological Liquids of Organism";
- iv. U.S. Patent No. 6,156,851 issued on December 5, 2000 and entitled "Material for Purification of Physiological Liquids of Organism";
- v. U.S. Patent No. 6,153,707 issued on November 28, 2000 and entitled "Method of Producing Material for Purification of Physiological Liquids of Organism";
- vi. U.S. Patent No. 6,136,424 issued on October 24, 2000 and entitled "Method of and Material for Purification of Physiological Liquids of Organism, and Method of Producing the Material";
- vii. U.S. Patent No. 6,133,393 issued on October 17, 2000 and entitled "Method of Purification of Physiological Liquids of Organism";
- viii. U.S. Patent No. 6,127,311 issued on October 2, 2000 and entitled "Method of Producing Material for Purification of Physiological Liquids of Organism";
- ix. U.S. Patent No. 6,114,466 issued on September 5, 2000 and entitled "Material for Purification of Physiological Liquids of Organism";
- x. U.S. Patent No. 6,087,300 issued on July 11, 2000 and entitled "Method of Producing Material for Purification of Physiological Liquids of Organism";
- xi. U.S. Patent No. 5,904,663 issued on May 18, 1999 and entitled "Method of Removing Beta-2 Microglobulin from Blood"; and
- xii. and U.S. Patent No. 5,773,384 issued on June 30, 1998 and entitled "Sorbents for Removing Toxicants from Blood or Plasma, and Method of Producing the Same" (collectively, the "MedaSorb Patents");

WHEREAS, MedaSorb is the assignee and owner of:

- i. U.S. Pat. App. Ser. No. 11/255,132 filed on October 19, 2005 and entitled "Biocompatible Devices, Systems, and Methods for Reducing Levels of Pro-Inflammatory or Anti-Inflammatory Stimulators or Mediators in the Blood";
- ii. U.S. Pat. App. Ser. No. 11/105,140 filed on April 13, 2005 and entitled "Devices, Systems, and Methods for Reducing Levels of Pro-Inflammatory or Anti-Inflammatory Stimulators or Mediators in the Blood";
- iii. U.S. Pat. App. Ser. No.10/981,055 filed on November 4, 2004 and entitled "Devices, Systems, and Methods for Reducing Levels of Pro-Inflammatory or Anti-Inflammatory Stimulators or Mediators in the Blood";
- iv. U.S. Pat. App. Ser. No.10/980,510 filed on November 3, 2004 and entitled "Devices, Systems, and Methods for Reducing Levels of Pro-Inflammatory or Anti-Inflammatory Stimulators or Mediators in the Blood, Generated as a Result of Extracorporeal Blood Processing"; and
- v. U.S. Pat. App. Ser. No. 10/038,053 filed on December 21, 2002 and entitled "Selective Adsorption Devices and Systems" (collectively, the "MedaSorb Patent Applications"); and

WHEREAS MedaSorb and Bro-Tech Corporation, having an office at 150 Monument Road, Bala Cynwyd, PA 19004 ("Bro-Tech"), have entered into a Stipulated Order and Settlement Agreement effective August 7, 2006 providing for the assignment to Bro-Tech of a certain interest in the MedaSorb Patents and the MedaSorb Patent Applications and for the grant back of an exclusive license from Bro-Tech to MedaSorb to practice the inventions in the MedaSorb Patents and MedaSorb Patent Applications and to enforce the same;

NOW, THEREFORE, in consideration of the sum of one dollar (\$1.00), the receipt of which is acknowledged and other good and valuable consideration:

1. MedaSorb hereby irrevocably sells, assigns, and transfers to Bro-Tech an equal, undivided ownership interest for the United States and its territorial possessions and in all foreign countries to the MedaSorb patents and to the inventions which are claimed in the MedaSorb Patents.

2. MedaSorb hereby irrevocably sells, assigns, and transfers to Bro-Tech an equal, undivided ownership interest for the United States and its territorial possessions and in all foreign countries to the MedaSorb Patent Applications, to the inventions which are disclosed in the MedaSorb Patent Applications and to any patents that might issue from the MedaSorb Patent Applications.

MEDASORB CORPORATION

By: Al Kraus

Its: President & CEO

Dated: August 22, 2006

PATENT